Sigyn Therapeutics, Inc. (SIGY)
USD 4.15
(3.75%)
USD 4.15
(3.75%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.38 Million USD | 27.67% |
| 2022 | 1.86 Million USD | 215.18% |
| 2021 | 592.96 Thousand USD | 36.54% |
| 2020 | 434.26 Thousand USD | -77.13% |
| 2019 | 1.89 Million USD | 3.91% |
| 2018 | 1.82 Million USD | 49.57% |
| 2017 | 1.22 Million USD | 160.12% |
| 2016 | 469.81 Thousand USD | 175.02% |
| 2015 | -626.23 Thousand USD | -659092.63% |
| 2014 | -95.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.88 Million USD | -27.98% |
| 2024 Q1 | 2.61 Million USD | 9.68% |
| 2023 Q2 | 2.82 Million USD | 18.72% |
| 2023 Q4 | 2.38 Million USD | -22.65% |
| 2023 FY | 2.38 Million USD | 27.67% |
| 2023 Q3 | 3.08 Million USD | 9.31% |
| 2023 Q1 | 2.37 Million USD | 27.18% |
| 2022 Q3 | 1.74 Million USD | 44.69% |
| 2022 Q4 | 1.86 Million USD | 7.4% |
| 2022 Q2 | 1.2 Million USD | 33.7% |
| 2022 Q1 | 899.46 Thousand USD | 51.69% |
| 2022 FY | 1.86 Million USD | 215.18% |
| 2021 Q2 | -151.4 Thousand USD | -126.51% |
| 2021 Q4 | 592.96 Thousand USD | 25.34% |
| 2021 FY | 592.96 Thousand USD | 36.54% |
| 2021 Q1 | 571.14 Thousand USD | 31.52% |
| 2021 Q3 | 473.09 Thousand USD | 412.48% |
| 2020 Q4 | 434.26 Thousand USD | -77.78% |
| 2020 Q2 | 1.89 Million USD | 0.02% |
| 2020 Q1 | 1.89 Million USD | -0.3% |
| 2020 FY | 434.26 Thousand USD | -77.13% |
| 2020 Q3 | 1.95 Million USD | 3.22% |
| 2019 Q4 | 1.89 Million USD | 1.61% |
| 2019 FY | 1.89 Million USD | 3.91% |
| 2019 Q3 | 1.86 Million USD | 3.2% |
| 2019 Q2 | 1.81 Million USD | 0.07% |
| 2019 Q1 | 1.8 Million USD | -0.98% |
| 2018 Q4 | 1.82 Million USD | 2.02% |
| 2018 Q3 | 1.79 Million USD | 4.59% |
| 2018 Q2 | 1.71 Million USD | 7.5% |
| 2018 Q1 | 1.59 Million USD | 30.39% |
| 2018 FY | 1.82 Million USD | 49.57% |
| 2017 Q4 | 1.22 Million USD | 5.14% |
| 2017 Q1 | 798.53 Thousand USD | 69.97% |
| 2017 FY | 1.22 Million USD | 160.12% |
| 2017 Q2 | 1.13 Million USD | 42.18% |
| 2017 Q3 | 1.16 Million USD | 2.37% |
| 2016 Q2 | 154.65 Thousand USD | 195.37% |
| 2016 Q3 | 405.88 Thousand USD | 162.45% |
| 2016 Q1 | -162.15 Thousand USD | 74.11% |
| 2016 FY | 469.81 Thousand USD | 175.02% |
| 2016 Q4 | 469.81 Thousand USD | 15.75% |
| 2015 Q3 | -559.00 USD | 0.0% |
| 2015 Q4 | -626.23 Thousand USD | -111927.37% |
| 2015 FY | -626.23 Thousand USD | -659092.63% |
| 2014 FY | -95.00 USD | 0.0% |
| 2014 Q4 | -95.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 182240.0% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 57.757% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 94.424% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1055.867% |
| Rebus Holdings, Inc. | 305 Thousand USD | -682.306% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 137.846% |
| Qrons Inc. | 351.42 Thousand USD | -578.956% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -283.382% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 94.507% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 11791.66% |
| Skye Bioscience, Inc. | -5.72 Million USD | 141.704% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 84.863% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 42.059% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -493.764% |
| SQZ Biotechnologies Company | -36.23 Million USD | 106.584% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -6.413% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -157.341% |
| Mesoblast Limited | 55.85 Million USD | 95.728% |
| Marizyme, Inc. | 18.56 Million USD | 87.15% |
| Genus plc | 190.6 Million USD | 98.748% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -6.718% |
| Pharming Group N.V. | 109.8 Million USD | 97.827% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -177.368% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -96.561% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -250.887% |
| ContraFect Corporation | -6.02 Million USD | 139.596% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1672.172% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -106.506% |
| IMV Inc. | 7.67 Million USD | 68.893% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 56.633% |
| MultiCell Technologies, Inc. | 90.04 USD | -2649871.124% |
| ONE Bio Corp. | 9.04 Million USD | 73.606% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 425.082% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 81.569% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -74.421% |
| Q BioMed Inc. | 4.06 Million USD | 41.231% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 92.191% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -136.776% |
| Biomind Labs Inc. | 711.4 Thousand USD | -235.399% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 96.059% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -19.338% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 81.369% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -563.322% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1606.699% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -11910.037% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -8.359% |
| GB Sciences, Inc. | 1.74 Million USD | -36.554% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1398.253% |
| HST Global, Inc. | 96.79 Thousand USD | -2365.089% |
| CSL Limited | 10.52 Billion USD | 99.977% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1057.05% |
| Halberd Corporation | 144.72 Thousand USD | -1548.713% |
| Enzolytics Inc. | 981.65 Thousand USD | -143.062% |
| Agentix Corp. | 37.63 Thousand USD | -6240.607% |
| Resverlogix Corp. | 6.45 Million USD | 63.013% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 454.49% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.118% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 105.075% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 66.256% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 11.909% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 126.992% |
| AVAX Technologies, Inc. | -5.9 Million USD | 140.419% |
| Zenith Capital Corp. | 10.06 Thousand USD | -23608.605% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.225% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1090.446% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -1350.397% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 13125.625% |
| Kadimastem Ltd | -253.1 Thousand USD | 1042.716% |
| Helix BioMedix, Inc. | -2.57 Million USD | 192.841% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 88.232% |
| BioStem Technologies, Inc. | 4.47 Million USD | 46.645% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1085.583% |
| LadRx Corporation | -2.03 Million USD | 217.165% |
| Cell Source, Inc. | 9.23 Million USD | 74.155% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -275.655% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -275.655% |
| NovAccess Global Inc. | 2.17 Million USD | -9.528% |
| Affymax, Inc. | -5.59 Million USD | 142.631% |
| Itoco Inc. | 228.3 Thousand USD | -945.108% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1654.579% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 51.865% |
| Mobile Lads Corp. | 484.23 Thousand USD | -392.746% |
| CytoDyn Inc. | 20.26 Million USD | 88.224% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 368884.235% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 25843.92% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 69.037% |
| SYBLEU INC | 473.71 Thousand USD | -403.687% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 46.466% |
| International Stem Cell Corporation | 2.59 Million USD | 7.875% |
| Bioxytran, Inc. | 1.89 Million USD | -25.653% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -3722.976% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -9.406% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 30.517% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 72.103% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -208.829% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 290.883% |
| Neutra Corp. | 52.18 Thousand USD | -4472.085% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 195.863% |
| PureTech Health plc | -167.19 Million USD | 101.427% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1074.257% |
| IXICO plc | -4.44 Million USD | 153.684% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 81.95% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 95.65% |
| CSL Limited | 10.52 Billion USD | 99.977% |
| Cellectis S.A. | -43.81 Million USD | 105.445% |